Log In
Print
BCIQ
Print
Print this Print this
 

CPX-351

  Manage Alerts
Collapse Summary General Information
Company Celator Pharmaceuticals Inc.
DescriptionLiposomal formulation of cytarabine and daunorubicin encapsulated at a 5:1 molar ratio using CombiPlex technology
Molecular Target DNA polymerase ; Topoisomerase II (TOP2)
Mechanism of ActionTopoisomerase II inhibitor; DNA polymerase inhibitor
Therapeutic ModalitySmall molecule: Combination

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today